ZA200705160B - Quinoline derivatives for the treatment of latent tuberculosis - Google Patents

Quinoline derivatives for the treatment of latent tuberculosis

Info

Publication number: ZA200705160B
Authority: ZA; South Africa
Prior art keywords: treatment; quinoline derivatives; latent tuberculosis; tuberculosis; latent
Prior art date: 2004-12-24

Application number

ZA200705160A

Inventor

Koenraad Jozef Lodewijk Marcel Andries

Anil Koul

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-24

Filing date

2007-06-22

Publication date

2008-09-25

2007-06-22 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2008-09-25 Publication of ZA200705160B publication Critical patent/ZA200705160B/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Quinoline Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

ZA200705160A 2004-12-24 2007-06-22 Quinoline derivatives for the treatment of latent tuberculosis ZA200705160B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP04078529		2004-12-24

Publications (1)

Publication Number	Publication Date
ZA200705160B true ZA200705160B (en)	2008-09-25

Family

ID=36736133

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200705160A ZA200705160B (en)	2004-12-24	2007-06-22	Quinoline derivatives for the treatment of latent tuberculosis

Country Status (9)

Country	Link
JP (5)	JP2006182755A (en)
KR (2)	KR101301573B1 (en)
CN (1)	CN101087608A (en)
BG (1)	BG66437B1 (en)
EA (1)	EA009779B1 (en)
ES (1)	ES2362886T3 (en)
JO (1)	JO2695B1 (en)
UA (1)	UA88766C2 (en)
ZA (1)	ZA200705160B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA97813C2 (en) *	2006-12-05	2012-03-26	Янссен Фармацевтика Н.В.	Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
CN103664877A (en) *	2013-12-25	2014-03-26	重庆医药工业研究院有限责任公司	Quinoline, preparation method and application of quinoline
EA201891644A1 (en) *	2016-03-07	2019-04-30	Зе Глобал Эллайенс Фо Тб Драг Девелопмент, Инк.	ANTIBACTERIAL CONNECTIONS AND THEIR APPLICATION
CN109384716B (en) *	2017-08-11	2021-06-29	海创药业股份有限公司	Deuterated quinoline compound and preparation and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6075024A (en) *	1991-11-27	2000-06-13	Sepracor Inc.	Methods for treating infection using optically pure (S)-lomefloxacin
RS52431B (en) *	2002-07-25	2013-02-28	Janssen Pharmaceutica N.V.	QUINOLINE DERIVATIVES AND THEIR USE AS MYCOBACTERIAL INHIBITORS
ES2306146T3 (en) *	2004-05-28	2008-11-01	Janssen Pharmaceutica Nv	USE OF SUBSTITUTED QUINOLINE DERIVATIVES FOR THE TREATMENT OF MICOBACTERIAL DISEASES RESISTANT TO PHARMACOS.

2005
- 2005-06-09 EA EA200500802A patent/EA009779B1/en unknown
- 2005-06-09 BG BG109180A patent/BG66437B1/en unknown
- 2005-06-09 KR KR1020050049439A patent/KR101301573B1/en not_active Expired - Lifetime
- 2005-06-09 JP JP2005170052A patent/JP2006182755A/en not_active Withdrawn
- 2005-12-06 JO JO2005194A patent/JO2695B1/en active
- 2005-12-08 ES ES05815816T patent/ES2362886T3/en not_active Expired - Lifetime
- 2005-12-08 CN CNA2005800447974A patent/CN101087608A/en active Pending
- 2005-12-09 UA UAA200511766A patent/UA88766C2/en unknown
2007
- 2007-06-22 ZA ZA200705160A patent/ZA200705160B/en unknown
2012
- 2012-11-12 JP JP2012248469A patent/JP2013049704A/en not_active Withdrawn
2013
- 2013-03-29 KR KR1020130034387A patent/KR20130041872A/en not_active Withdrawn
2015
- 2015-05-01 JP JP2015094241A patent/JP6426530B2/en not_active Expired - Lifetime
2017
- 2017-03-22 JP JP2017056728A patent/JP2017141262A/en active Pending
- 2017-03-22 JP JP2017055989A patent/JP2017141259A/en active Pending

Also Published As

Publication number	Publication date
BG66437B1 (en)	2014-07-31
UA88766C2 (en)	2009-11-25
JP2006182755A (en)	2006-07-13
JP2013049704A (en)	2013-03-14
JP2015157847A (en)	2015-09-03
KR20060073416A (en)	2006-06-28
JP2017141262A (en)	2017-08-17
KR101301573B1 (en)	2013-09-04
EA200500802A1 (en)	2006-06-30
KR20130041872A (en)	2013-04-25
JP6426530B2 (en)	2018-11-21
EA009779B1 (en)	2008-04-28
ES2362886T3 (en)	2011-07-14
CN101087608A (en)	2007-12-12
JO2695B1 (en)	2013-03-03
JP2017141259A (en)	2017-08-17
BG109180A (en)	2006-06-30

Publication	Publication Date	Title
IL184123A0 (en)	2008-12-29	Quinoline derivatives for the treatment of latent tuberculosis
AP2037A (en)	2009-10-09	Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
PT1802579E (en)	2014-02-17	Derivatives of 3-arylaminopyridine
IL181524A0 (en)	2007-07-04	Heterocyclic compounds and methods of use
IL176629A0 (en)	2006-10-31	Sulfonamide derivatives for the treatment of diseases
AP2006003669A0 (en)	2006-06-30	Sulfonamide derivatives for the treatment of diseases
IL177232A0 (en)	2006-12-10	Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
IL180721A0 (en)	2007-06-03	Nicotinic receptor agonists for the treatment of inflammatory diseases
ZA200703884B (en)	2009-07-29	S-mirtazapine for the treatment of hot flush
ZA200705160B (en)	2008-09-25	Quinoline derivatives for the treatment of latent tuberculosis
EP1750698A4 (en)	2010-06-02	5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
IL179670A0 (en)	2007-05-15	Heterocyclic compounds and processes for the preparation thereof
ZA200800921B (en)	2009-06-24	Pyrazolone derivatives for the treatment of tuberculosis
PL1727545T3 (en)	2013-01-31	Use of n-piperidine derivatives for the treatment of neurodegenerative pathologies
ZA200608015B (en)	2008-12-31	Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
GB0408297D0 (en)	2004-05-19	Indole derivatives for the treatment of diseases
GB0412299D0 (en)	2004-07-07	Method for the synthesis of halogenated heterocycles
IL176564A0 (en)	2006-10-31	Sulfonamide derivatives for the treatment of diseases
GB0406387D0 (en)	2004-04-21	Sulfonamide derivatives for the treatment of diseases
GB0406388D0 (en)	2004-04-21	Sulfonamide derivatives for the treatment of diseases
GB0224232D0 (en)	2002-11-27	Use of fluoroquinolone antibodies for the treatment of anthrax
PL372016A1 (en)	2006-07-10	Method for the manufacture of derivatives of n-phenyl-2-pyrimidinamines